#1 Clinical Trials Search in Europe

Tazobactam

Tazobactam is an important drug used in combination with other antibiotics to treat various bacterial infections. This article examines recent clinical trials investigating the use of tazobactam, particularly in combination with piperacillin and ceftolozane, for conditions like sepsis, pneumonia, and infections in patients with cystic fibrosis or burns. The trials aim to optimize dosing regimens, evaluate efficacy and safety, and explore new applications for these combination antibiotics in different patient populations.

Table of Contents

What is Tazobactam?

Tazobactam is an important medication used in the treatment of various bacterial infections. It belongs to a class of drugs called beta-lactamase inhibitors. Tazobactam is not typically used alone but is combined with other antibiotics to enhance their effectiveness[1].

How Tazobactam Works

Tazobactam works by blocking the action of certain enzymes (called beta-lactamases) that some bacteria produce. These enzymes can break down certain antibiotics, making them ineffective. By inhibiting these enzymes, tazobactam helps the antibiotic it’s paired with to work more effectively against bacterial infections[2].

Conditions Treated with Tazobactam

Tazobactam, in combination with other antibiotics, is used to treat a variety of serious bacterial infections, including:

  • Septic shock: A life-threatening condition caused by a severe infection that spreads throughout the body[1]
  • Ventilator-associated pneumonia (VAP): A lung infection that develops in people who are on mechanical ventilation[3]
  • Intra-abdominal infections: Infections within the abdomen[2]
  • Complicated urinary tract infections: Serious infections of the urinary system[2]
  • Infections in patients with cystic fibrosis and bronchiectasis: Lung conditions that make patients more susceptible to infections[4]
  • Late-onset neonatal sepsis: A serious blood infection in newborn babies[5]

Combination with Other Antibiotics

Tazobactam is most commonly combined with the following antibiotics:

  • Piperacillin: This combination is known as Piperacillin/Tazobactam (often abbreviated as PIP/TAZO). It may also be sold under brand names such as Tazocin, Zosyn, Tazonam, or Tazovak[6]
  • Ceftolozane: This combination is known as Ceftolozane/Tazobactam and is sold under the brand name Zerbaxa[7]

Dosage and Administration

The dosage of tazobactam (in combination with other antibiotics) can vary depending on the specific infection being treated, the patient’s age, weight, and kidney function. It is typically given intravenously (through a vein) in a hospital or healthcare setting. The duration of treatment can range from 5 to 14 days, depending on the severity and type of infection[4][5].

In some cases, continuous infusion over 24 hours may be used, especially for outpatient treatment of certain conditions[4].

Use in Special Populations

Tazobactam combinations are used in various patient groups, including:

  • Critically ill patients: Those with severe infections or septic shock[8]
  • Patients with burns: Special dosing may be required due to changes in how the body processes drugs after severe burns[7]
  • Premature infants: Careful dosing is necessary for treating infections in very young babies[5]
  • Patients with kidney problems: Dose adjustments may be needed based on kidney function[6]

Ongoing Research and Clinical Trials

Several clinical trials are currently underway to further study the effectiveness and optimal dosing of tazobactam combinations in various patient populations. These studies aim to improve treatment outcomes and develop better dosing strategies for different types of infections[2][4][5].

Potential Side Effects

Like all medications, tazobactam combinations can cause side effects. Common side effects may include:

  • Nausea
  • Diarrhea
  • Headache
  • Vomiting
  • Constipation
  • Insomnia (difficulty sleeping)
  • Rash
  • Fever

More serious side effects can include liver function abnormalities and kidney problems. Your healthcare provider will monitor you for these potential issues during treatment[4].

Aspect Details
Drug Combinations Piperacillin/tazobactam, Ceftolozane/tazobactam
Conditions Studied Sepsis, Pneumonia, Cystic fibrosis, Bronchiectasis, Burns, Infections due to resistant bacteria
Patient Populations Critically ill, Burn patients, Premature infants, Cystic fibrosis patients
Dosing Strategies Extended infusions, Continuous infusions, Model-based dosing
Key Outcomes Measured Clinical response, Mortality, Hospital stay duration, Microbiological response, Antibiotic resistance development
Safety Assessments Adverse events, Drug tolerability, Kidney and liver function monitoring

FAQ

  • What is tazobactam and how is it used? Tazobactam is a beta-lactamase inhibitor that is used in combination with other antibiotics like piperacillin or ceftolozane. It helps prevent bacteria from breaking down the antibiotic, making the treatment more effective against certain resistant bacteria.
  • What conditions are being studied using tazobactam combinations? Clinical trials are exploring the use of tazobactam combinations for various conditions including sepsis, pneumonia, infections in cystic fibrosis and bronchiectasis patients, burns, and infections caused by resistant bacteria like Pseudomonas aeruginosa.
  • How is dosing being optimized in these trials? Several trials are examining different dosing regimens, including extended and continuous infusions, to optimize drug levels in the body. They are also looking at how factors like kidney function and body weight affect proper dosing.
  • Are these antibiotics being studied in special populations? Yes, the trials include studies in populations like critically ill patients, those with burns, premature infants, and patients with cystic fibrosis or bronchiectasis. This helps determine safe and effective use in these specific groups.
  • What are some of the outcomes being measured in these trials? The trials are measuring outcomes such as clinical response, mortality rates, length of hospital stay, microbiological response (bacterial elimination), development of antibiotic resistance, and occurrence of side effects.

Ongoing Clinical Trials on Tazobactam

  • Study on Avibactam and Drug Combination for Treating Severe Infections in Patients

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Greece

Glossary

  • Beta-lactamase inhibitor: A substance that prevents bacteria from breaking down certain antibiotics, making the antibiotic more effective against resistant bacteria.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Minimum Inhibitory Concentration (MIC): The lowest concentration of an antibiotic that prevents visible growth of a bacterium.
  • Extended-spectrum beta-lactamases (ESBL): Enzymes produced by some bacteria that can break down and cause resistance to certain antibiotics.
  • Multidrug-resistant (MDR): Bacteria that are resistant to multiple types of antibiotics.
  • Sepsis: A life-threatening condition caused by the body's extreme response to an infection, which can lead to tissue damage, organ failure, and death.
  • Ventilator-Associated Pneumonia (VAP): A type of lung infection that occurs in people who are on mechanical ventilation breathing machines in hospitals.
  • Bronchiectasis: A chronic condition where the airways of the lungs become abnormally widened, leading to a build-up of excess mucus that makes the lungs more vulnerable to infection.
  • Cystic Fibrosis: A genetic disorder that affects mostly the lungs, but also the pancreas, liver, kidneys, and intestine. It causes the body to produce thick and sticky mucus that can clog the lungs and obstruct the pancreas.

References

  1. https://clinicaltrials.gov/study/NCT02820987
  2. https://clinicaltrials.gov/study/NCT06422533
  3. https://clinicaltrials.gov/study/NCT01853982
  4. https://clinicaltrials.gov/study/NCT06035055
  5. https://clinicaltrials.gov/study/NCT05981079
  6. https://clinicaltrials.gov/study/NCT00816790
  7. https://clinicaltrials.gov/study/NCT03002506
  8. https://clinicaltrials.gov/study/NCT02730624